Platform

Discovering, developing, and manufacturing next generation live biotherapeutics

Our state-of-the-art plat­form enables an unprece­dent­ed under­stand­ing of host-micro­bio­me inter­ac­tion and pro­vides an effi­cient approach to drug discovery.

Platform graphic featuring the for pieces of the Kanvas platform: Characterization, Selection, Manufacturing, and Translation. They all point toward the center goal text: "Next Generation Live Biotherapeutics"

  • Mechanism

    Visualization of host-microbiome interaction in situ

  • Manufacturing

    Reproducible large-scale manufacturing of complex consortia

  • Complexity

    Formulating live biotherapeutics that optimize healthy human-gut microbiome

A novel approach, from microbiome profiling to high-throughput drug manufacturing.

A plat­form for dis­cov­er­ing, devel­op­ing, and man­u­fac­tur­ing next-gen­er­a­tion live bio­ther­a­peu­tics takes advan­tage of our foun­da­tion­al under­stand­ing of the micro­bio­me, address­ing all FDA require­ments and accel­er­at­ing crit­i­cal steps along the drug devel­op­ment pathway.

HiPR-FISH Tech­nol­o­gy

Mapping host-microbiome interactions in situ at high resolution & multiplexity

We simul­ta­ne­ous­ly iden­ti­fy host-cell tran­scripts and micro­bial tax­on­o­my. By pro­fil­ing host-micro­bio­me inter­ac­tion in situ, we can gain an unprece­dent­ed under­stand­ing of the micro­bio­me for nov­el ther­a­peu­tic development.

A mixture of highlighted microbes interacting, differentiated by their bright pink and green colors
Kanvas’ imaging platform is capable of rapid microbial identification and characterization in complex communities.
Nature article by Hao Shi

ACT™ Man­u­fac­tur­ing: Anaer­o­bic Co-cul­ture Technology

Manufacturing consortia from purified cell lines

We co-cul­ture com­mu­ni­ties of iso­lat­ed strains at an indus­tri­al scale with our state-of-the-art pro­duc­tion technology.

A scientist working in the lab at Kanvas Bio headquarters

Plat­form Partnerships

We work with partners to better understand the microbiome and its role in disease and drug candidates.

We have a vast part­ner­ship net­work made up of some of the top biotech­nol­o­gy and phar­ma­ceu­ti­cal com­pa­nies in the sci­en­tif­ic community.

"The University of Texas MD Anderson Cancer Center"
Work with us
OUR PIPELINE

Our pipeline enables rapid screen­ing of sev­er­al drug can­di­dates for dif­fer­ent dis­eases to ben­e­fit patients as soon as possible.